• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by AC Immune SA (Amendment)

    2/14/22 1:41:00 PM ET
    $ACIU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACIU alert in real time by email
    SC 13G/A 1 sc13ga507422aciu_02142022.htm AMENDMENT NO. 5 TO THE SCHEDULE 13G

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 5)1

     

    AC Immune SA

     (Name of Issuer)

    Common Shares, par value CHF 0.02

     (Title of Class of Securities)

    H00263105

     (CUSIP Number)

    December 31, 2021

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. H00263105

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Fund, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         3,648,633  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              3,648,633  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,648,633  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.0%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. H00263105

      1   NAME OF REPORTING PERSON  
             
            BVF I GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         3,648,633  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              3,648,633  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,648,633  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.0%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. H00263105

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Trading Fund II, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         2,862,430  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              2,862,430  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,862,430  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.9%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    4

    CUSIP No. H00263105

     

      1   NAME OF REPORTING PERSON  
             
            BVF II GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         2,862,430  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              2,862,430  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,862,430  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.9%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    5

    CUSIP No. H00263105

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Trading Fund OS LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         420,150  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              420,150  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            420,150  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    6

    CUSIP No. H00263105

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners OS Ltd.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         420,150  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              420,150  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            420,150  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1%  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    7

    CUSIP No. H00263105

     

      1   NAME OF REPORTING PERSON  
             
            BVF GP Holdings LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         6,511,063  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              6,511,063  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            6,511,063  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            9.0%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    8

    CUSIP No. H00263105

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         7,062,379  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              7,062,379  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            7,062,379  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            9.7%  
      12   TYPE OF REPORTING PERSON  
             
            PN, IA  

      

    9

    CUSIP No. H00263105

     

      1   NAME OF REPORTING PERSON  
             
            BVF Inc.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         7,062,379  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              7,062,379  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            7,062,379  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            9.7%  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    10

    CUSIP No. H00263105

     

      1   NAME OF REPORTING PERSON  
             
            Mark N. Lampert  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            United States  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         7,062,379  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              7,062,379  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            7,062,379  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            9.7%  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    11

    CUSIP No. H00263105

    Item 1(a).Name of Issuer:

     

    AC Immune SA, a Switzerland corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    EPFL Innovation Park, Building B

    1015 Lausanne, Switzerland

     

    Item 2(a).Name of Person Filing
    Item 2(b).Address of Principal Business Office or, if None, Residence
    Item 2(c).Citizenship

     

    Biotechnology Value Fund, L.P. (“BVF”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF I GP LLC (“BVF GP”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Fund II, L.P. (“BVF2”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF II GP LLC (“BVF2 GP”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Trading Fund OS LP (“Trading Fund OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    BVF Partners OS Ltd. (“Partners OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    BVF GP Holdings LLC (“BVF GPH”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    12

    CUSIP No. H00263105

    BVF Partners L.P. (“Partners”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF Inc.

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Mark N. Lampert (“Mr. Lampert”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: United States

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    Item 2(d).Title of Class of Securities:

     

    Common Shares, par value CHF 0.02 per share (the “Shares”).

     

    Item 2(e).CUSIP Number:

     

    H00263105

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    13

    CUSIP No. H00263105

    Item 4.Ownership

     

    (a)Amount beneficially owned:

    As of the close of business on December 31, 2021 (i) BVF beneficially owned 3,648,633 Shares, (ii) BVF2 beneficially owned 2,862,430 Shares, and (iii) Trading Fund OS beneficially owned 420,150 Shares.

     

    BVF GP, as the general partner of BVF, may be deemed to beneficially own the 3,648,633 Shares beneficially owned by BVF.

     

    BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 2,862,430 Shares beneficially owned by BVF2.

     

    Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 420,150 Shares beneficially owned by Trading Fund OS.

     

    BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 6,511,063 Shares beneficially owned in the aggregate by BVF and BVF2.

     

    Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 7,062,379 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS, and held in a certain Partners managed account (the “Partners Managed Account”), including 131,166 Shares held in the Partners Managed Account.

     

    BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 7,062,379 Shares beneficially owned by Partners.

     

    Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 7,062,379 Shares beneficially owned by BVF Inc.

     

    The foregoing should not be construed in and of itself as an admission by any Reporting

    Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

     

    14

    CUSIP No. H00263105

    (b)Percent of class:

     

    The following percentages are based on 72,652,654 Shares outstanding as of March 31, 2021, as disclosed in the Issuer’s Prospectus Supplement filed on Form 424B5 filed with the Securities and Exchange Commission on April 28, 2021.

     

    As of the close of business on December 31, 2021, (i) BVF beneficially owned approximately 5.0% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 3.9% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 5.0% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 3.9% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 9.0% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.7% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).

      

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (ii)Shared power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (iii)Sole power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    15

    CUSIP No. H00263105

    (iv)Shared power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Exhibit 99.1 to Amendment No. 3 to the Schedule 13G filed with the Securities and Exchange Commission on February 14, 2020.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    16

    CUSIP No. H00263105

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: Februrary 14, 2022

     

    BIOTECHNOLOGY VALUE FUND, L.P.   Biotechnology Value Trading Fund OS LP
         
    By: BVF I GP LLC., its general partner      
          By: BVF Partners L.P., its investment manager
    By:

    /s/ Mark N. Lampert

      By: BVF Inc., its general partner
      Mark N. Lampert      
      Chief Executive Officer   By: /s/ Mark N. Lampert
            Mark Lampert
            President
    BVF I GP LLC      
             
    By: /s/ Mark N. Lampert   BVF GP HOLDINGS LLC
      Mark N. Lampert      
      Chief Executive Officer   By: /s/ Mark N. Lampert
            Mark Lampert
            Chief Executive Officer
    BIOTECHNOLOGY VALUE FUND II, L.P.    
             
    By: BVF II GP LLC its general partner   BVF PARTNERS L.P.
             
    By:

    /s/ Mark N. Lampert

      By: BVF Inc., its general partner
      Mark N. Lampert      
      Chief Executive Officer   By: /s/ Mark N. Lampert
            Mark N. Lampert
            President
    BVF II GP LLC      
             
    By: /s/ Mark N. Lampert   BVF INC.
      Mark N. Lampert      
      Chief Executive Officer   By: /s/ Mark N. Lampert
            Mark Lampert
            President
    BVF PARTNERS OS LTD.      
             
    By: BVF Partners L.P., its sole member   /s/ Mark N. Lampert
    By: BVF Inc., its general partner   MARK N. LAMPERT
             
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert      
      President      

    17

     

    Get the next $ACIU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACIU

    DatePrice TargetRatingAnalyst
    5/31/2024$8.00Buy
    BTIG Research
    12/20/2021$17.00 → $15.00Outperform
    SVB Leerink
    More analyst ratings

    $ACIU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by AC Immune SA

      SC 13G/A - AC Immune SA (0001651625) (Subject)

      12/13/24 5:15:16 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by AC Immune SA

      SC 13G/A - AC Immune SA (0001651625) (Subject)

      11/14/24 4:36:20 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AC Immune SA (Amendment)

      SC 13G/A - AC Immune SA (0001651625) (Subject)

      2/9/24 4:30:11 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACIU
    SEC Filings

    See more
    • SEC Form 6-K filed by AC Immune SA

      6-K - AC Immune SA (0001651625) (Filer)

      4/30/25 7:15:09 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AC Immune SA

      6-K - AC Immune SA (0001651625) (Filer)

      3/13/25 7:32:22 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by AC Immune SA

      20-F - AC Immune SA (0001651625) (Filer)

      3/13/25 7:30:34 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACIU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

      AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold higher than placebo after 4 immunizationsRepeated immunizations amplify the anti-a-syn antibody response, supporting boostability and the potential to further increase antibody titersACI-7104.056 is well tolerated with no safety issues reported to date Lausanne, Switzerland, April 2, 2025 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced

      4/2/25 6:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

      AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company's industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseasesMultiple presentations at the International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) showcasing the diversity of the company's precision medicine pipeline Lausanne, Switzerland, March 25, 2025 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine

      3/25/25 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune to Participate in Upcoming Investor Conferences

      AC Immune to Participate in Upcoming Investor Conferences Lausanne, Switzerland, March 4, 2025 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the company's management will participate in the following investor conferences in March: Leerink Partners 2025 Global Healthcare Conference,Management will participate in investor meetings on March 10, 2025Barclays 27th Annual Global Healthcare Conference,Management will participate in investor meetings on March 11, 2025 Please contact your Leerink or Barclays representative or AC Immune to request a one-on-one meeting with AC Immune's manag

      3/4/25 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACIU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on AC Immune with a new price target

      BTIG Research initiated coverage of AC Immune with a rating of Buy and set a new price target of $8.00

      5/31/24 7:33:11 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on AC Immune with a new price target

      SVB Leerink reiterated coverage of AC Immune with a rating of Outperform and set a new price target of $15.00 from $17.00 previously

      12/20/21 4:45:45 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on AC Immune with a new price target

      HC Wainwright & Co. reiterated coverage of AC Immune with a rating of Buy and set a new price target of $16.00 from $11.00 previously

      3/24/21 6:35:50 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACIU
    Financials

    Live finance-specific insights

    See more
    • AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease

      AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer's disease progressionAC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billionAC Immune to host conference call and webcast today at 8:30 a.m. ET OSAKA, Japan, CAMBRIDGE, Massachusetts, and LAUSANNE, Switzerland, May 13, 2024 – Takeda (NYSE:TAK) and AC Immune SA (NASDAQ:ACIU)

      5/13/24 6:00:00 AM ET
      $ACIU
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune acquires AFFiRiS' Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases

      AFFiRiS to receive AC Immune stock valued at USD 58.7 million in exchange for its portfolio of therapeutics targeting alpha-synuclein and USD 5 million in cashAFFiRiS to focus on partnering to further develop its SAIT and monoclonal antibody for cardiovascular disease and for Huntington's disease, respectively VIENNA, Austria, July 27, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company that has been engaged in the development of novel disease-modifying Specific Active Immunotherapies (SAITs), today announced that AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, is acquiring AFFiRiS

      7/27/21 8:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH

      All-stock transaction maintains AC Immune's strong cash position USD 25 million private placement led by premier investor Athos Service GmbH Transactions expand and accelerate AC Immune's therapeutic development in Parkinson's disease AC Immune to immediately launch clinical development of acquired vaccine into an adaptive, biomarker-based Phase 2 study in Parkinson's disease Conference call scheduled today at 8:30 am ET / 2:30 pm CET LAUSANNE, Switzerland, July 27, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it is acquiring Affiris' portfoli

      7/27/21 7:30:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACIU
    Leadership Updates

    Live Leadership Updates

    See more
    • AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

      AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSORetiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handoverChristopher Roberts, Interim Chief Financial Officer, confirmed in role on a permanent basis Lausanne, Switzerland, December 1, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment, as of January 1st, 2024, of Dr. Madiha Derouazi as Chief Scientific Officer and the promotion of Interim Chief Financial Off

      12/1/23 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune SA Appoints New Chief Medical Officer

      AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 26, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment of Nuno Mendonça, MD. He will join the Company on October 1st, as Chief Medical Officer and be appointed to the Executive Committee. Johannes Streffer, MD, currently Chief Medical Officer, will leave at the end of September to pursue a new role. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: "It is with great pleasure that we welcome Dr Mendonça to our

      7/26/23 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors

      Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization Prof. Bütler is a leading Swiss economist and former Vice President of the independent Swiss COVID-19 Science Taskforce LAUSANNE, Switzerland, Oct. 29, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held an extraordinary general meeting (EGM) and elected Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors. Dr. Shaw and Prof. Bütler replace Mr. M

      10/29/21 6:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care